Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.-论文-万方医学网

第一作者： Rodabe N,Amaria

第一单位： Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

作者： Rodabe N,Amaria ^[1] ; Peter A,Prieto ^[2] ; Michael T,Tetzlaff ^[3] ; Alexandre,Reuben ^[2] ; Miles C,Andrews ^[2] ; Merrick I,Ross ^[2] ; Isabella C,Glitza ^[1] ; Janice,Cormier ^[2] ; Wen-Jen,Hwu ^[1] ; Hussein A,Tawbi ^[1] ; Sapna P,Patel ^[1] ; Jeffrey E,Lee ^[2] ; Jeffrey E,Gershenwald ^[2] ; Christine N,Spencer ^[4] ; Vancheswaran,Gopalakrishnan ^[2] ; Roland,Bassett ^[5] ; Lauren,Simpson ^[1] ; Rosalind,Mouton ^[1] ; Courtney W,Hudgens ^[3] ; Li,Zhao ^[4] ; Haifeng,Zhu ^[1] ; Zachary A,Cooper ^[6] ; Khalida,Wani ^[3] ; Alexander,Lazar ^[3] ; Patrick,Hwu ^[1] ; Adi,Diab ^[1] ; Michael K,Wong ^[1] ; Jennifer L,McQuade ^[1] ; Richard,Royal ^[2] ; Anthony,Lucci ^[2] ; Elizabeth M,Burton ^[2] ; Sangeetha,Reddy ^[7] ; Padmanee,Sharma ^[8] ; James,Allison ^[9] ; Phillip A,Futreal ^[4] ; Scott E,Woodman ^[1] ; Michael A,Davies ^[1] ; Jennifer A,Wargo ^[10]

作者单位： Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[1] Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[2] Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[3] Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[4] Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[5] Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[6] Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[7] Department of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[8] Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[9] Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jwargo@mdanderson.org. ^[10]

主题词医学科学研究中心(Academic Medical Centers);成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌症医护设施(Cancer Care Facilities);化学疗法, 辅助(Chemotherapy, Adjuvant);置信区间(Confidence Intervals);无病生存(Disease-Free Survival);人类(Humans);咪唑类(Imidazoles);黑色素瘤(Melanoma);中年人(Middle Aged);Mohs外科手术(Mohs Surgery);肿瘤辅助疗法(Neoadjuvant Therapy);肿瘤侵润(Neoplasm Invasiveness);肿瘤分期(Neoplasm Staging);肟类(Oximes);预后(Prognosis);吡啶酮类(Pyridones);嘧啶酮类(Pyrimidinones);危险性评估(Risk Assessment);皮肤肿瘤(Skin Neoplasms);护理标准(Standard of Care);存活率分析(Survival Analysis);得克萨斯(Texas);治疗结果(Treatment Outcome)

DOI 10.1016/S1470-2045(18)30015-9

PMID 29361468

发布时间 2022-03-30

检索历史清除

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

The Lancet. Oncology

相似文献

The Lancet. Oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

The Lancet. Oncology

相似文献

The Lancet. Oncology

相关期刊

检索历史清除